| Autor: |
Natasha M. Kafai, Richard D. Head, Jon H. Ritter, Michael J. Holtzman, Jinsheng Yu, Michael S. Diamond, Julie M. Fox, Sarah Dort, Shamus P. Keeler, Emma S. Winkler, Liang I. Kang, Adam L. Bailey, Broc T. McCune, Annette Robichaud, James T. Earnest, Sharmila Nair, Rita E. Chen |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
bioRxiv |
| Popis: |
Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) emerged in late 2019 and has spread worldwide resulting in the Coronavirus Disease 2019 (COVID-19) pandemic. Although animal models have been evaluated for SARS-CoV-2 infection, none have recapitulated the severe lung disease phenotypes seen in hospitalized human cases. Here, we evaluate heterozygous transgenic mice expressing the human ACE2 receptor driven by the epithelial cell cytokeratin-18 gene promoter (K18-hACE2) as a model of SARS-CoV-2 infection. Intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice results in high levels of viral infection in lung tissues with additional spread to other organs. Remarkably, a decline in pulmonary function, as measured by static and dynamic tests of respiratory capacity, occurs 4 days after peak viral titer and correlates with an inflammatory response marked by infiltration into the lung of monocytes, neutrophils, and activated T cells resulting in pneumonia. Cytokine profiling and RNA sequencing analysis of SARS-CoV-2-infected lung tissues show a massively upregulated innate immune response with prominent signatures of NF-kB-dependent, type I and II interferon signaling, and leukocyte activation pathways. Thus, the K18-hACE2 model of SARS-CoV-2 infection recapitulates many features of severe COVID-19 infection in humans and can be used to define the mechanistic basis of lung disease and test immune and antiviral-based countermeasures. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
